Fishman Jay A Ltd. MI Trims Position in Danaher Co. (NYSE:DHR)

Fishman Jay A Ltd. MI trimmed its position in Danaher Co. (NYSE:DHR) by 3.2% during the 4th quarter, HoldingsChannel reports. The firm owned 14,181 shares of the conglomerate’s stock after selling 475 shares during the period. Fishman Jay A Ltd. MI’s holdings in Danaher were worth $3,255,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Quent Capital LLC grew its position in shares of Danaher by 7.8% during the 4th quarter. Quent Capital LLC now owns 2,840 shares of the conglomerate’s stock valued at $652,000 after acquiring an additional 205 shares during the period. Catawba River Capital raised its holdings in Danaher by 1.9% in the 4th quarter. Catawba River Capital now owns 28,117 shares of the conglomerate’s stock worth $6,454,000 after purchasing an additional 517 shares during the period. Single Point Partners LLC purchased a new position in Danaher during the fourth quarter valued at $215,000. Sovran Advisors LLC bought a new stake in Danaher during the fourth quarter valued at about $677,000. Finally, First Fiduciary Investment Counsel Inc. increased its position in Danaher by 1.8% in the fourth quarter. First Fiduciary Investment Counsel Inc. now owns 42,796 shares of the conglomerate’s stock worth $9,824,000 after buying an additional 741 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.2 %

NYSE DHR opened at $201.15 on Wednesday. The stock has a 50 day moving average price of $231.96 and a 200-day moving average price of $251.14. Danaher Co. has a one year low of $199.75 and a one year high of $281.70. The company has a market capitalization of $145.29 billion, a P/E ratio of 38.10, a P/E/G ratio of 2.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the company earned $2.09 earnings per share. As a group, equities analysts predict that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.54%. Danaher’s payout ratio is currently 20.45%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DHR. TD Cowen lifted their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. UBS Group reduced their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Stephens restated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, Barclays cut their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.